PARP1 and breast carcinoma: In this study, we evaluated the effects of 3 different PARP inhibitors, ABT-888, BSI-201 and AZD228, in BRCA mutant breast cancer cell lines as single agents without DNA damaging agents; such a study has not been performed previously.